Lower limb infections, as the sum of all the infections affecting every single lower anatomical compartment (Supplementary Table S5), were detailed in 31 trials (3, 6, 3, 16, and 3 with canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin, respectively) for a total of 585 events with SGLT2-is versus 456 events with comparators, thus resulting in a global RRMH of 1.20 [1.02–1.40] (Figure 9). This evidence concerns the gene SLC5A2 and infection.